<DOC>
	<DOCNO>NCT00002414</DOCNO>
	<brief_summary>The purpose study see safe effective give CPI-1189 patient AIDS dementia . Advanced HIV infection cause AIDS dementia ( brain damage due HIV leading loss memory muscle control ) . CPI-1189 may able postpone AIDS dementia slow .</brief_summary>
	<brief_title>Safety Effectiveness Giving CPI-1189 HIV-Infected Patients With AIDS Dementia</brief_title>
	<detailed_description>Late-stage HIV infection cause AIDS dementia ( brain damage due HIV leading loss memory muscle control ) . CPI-1189 may able postpone AIDS dementia slow . Patients randomize receive either placebo one two oral dos CPI-1189 daily . Patients assess safety tolerability Weeks 2 , 6 , 10 . At Week 10 , efficacy assessment also make . For volunteer , sample cerebrospinal fluid obtain baseline Week 10 . Blood sample CPI-1189 pharmacokinetic trough measurement take Weeks 2 10 . The open-label phase start Week 11 . At Weeks 13 16 , safety evaluation perform . At end open-label phase , Week 22 , final set safety efficacy assessment blood sample CPI-1189 pharmacokinetic trough measurement obtain .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Are least 18 year old . Have symptom AIDS dementia include forgetfulness , loss concentration , slow mental processing , loss muscle control . Have stable antiHIV drug therapy past 6 week ( take antiHIV drug ) . Exclusion Criteria You eligible study : Have certain serious medical condition , mental disorder opportunistic ( AIDSrelated ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>AIDS Dementia Complex</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>